Skip to content
Screener

Zevra Therapeutics, Inc. ZVRA Cash and cash equivalents, end of period

Cash and cash equivalents, end of period at other companies

Mirum Pharmaceuticals, Inc. logo
Mirum Pharmaceuticals, Inc.MIRM
$332.46M+45.4%
BridgeBio Pharma logo
BridgeBio PharmaBBIO
$680.04M-9.5%
Polaryx Therapeutics, Inc. logo
Polaryx Therapeutics, Inc.PLYX
——

Other financials

Income statement

See full
Revenue$39.7M+53.3%
Gross profit$38.1M+182%
Operating income$16.8M+124%
Net income$8.8M-88.3%
EPS (diluted)$0.14-88.4%

Balance sheet

See full
Cash & equivalents$145.3M+205%
Total debt$1.5M-97.6%
Total equity$217.7M+85.7%
Total assets$302.7M+18.1%

Cash flow

See full
Operating cash flow$17.0M+573%
CapEx$217.0K+1.9%
Free cash flow$16.8M+541%

Valuation

See full
Market cap$686.48M+7.3%
Enterprise value$542.65M-17.1%
P/E11.8×-230×
P/S5×-5.3×

Profitability

See full
Gross margin95.5%+23.5pp
Operating margin-103.9%-43.0pp
Net margin42.8%+38.6pp
FCF margin-75%-30.5pp

Returns & leverage

See full
Return on equity34.8%+31.3pp
Debt / equity0×-0.5×
Current ratio5.2×-2.7×

Where this comes from

Reported directly by Zevra Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations.

The source filing: Zevra Therapeutics, Inc.’s 10-Q, filed August 5, 2026.

Filed
Aug 5, 2026, 5:19 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001434647-26-000068
Line itemSix months ended June 30, 2026Six months ended June 30, 2025
Effect of exchange rate changes on cash and cash equivalents(109)286
Net increase in cash and cash equivalents82,91513,927
Cash and cash equivalents, beginning of period62,40633,785
Cash and cash equivalents, end of period$145,321$47,712
Supplemental cash flow information:
Cash paid for interest$1,370$2,626
Right-of-use assets obtained in exchange for lease liabilities4601,115
Cash paid for income taxes3,178—

ITEM 1.FINANCIAL STATEMENTS

FAQ

What is Zevra Therapeutics, Inc.'s cash and cash equivalents, end of period?
Zevra Therapeutics, Inc. (ZVRA) reported cash and cash equivalents, end of period of $145.32M in Q2 2026.
How has Zevra Therapeutics, Inc.'s cash and cash equivalents, end of period changed year-over-year?
Zevra Therapeutics, Inc.'s cash and cash equivalents, end of period increased by 204.6% year-over-year, from $47.71M to $145.32M.
What is the long-term trend for Zevra Therapeutics, Inc.'s cash and cash equivalents, end of period?
Over 2 years (2023 to 2025), Zevra Therapeutics, Inc.'s cash and cash equivalents, end of period has grown at a 20.4% compound annual growth rate (CAGR), from $43.05M to $62.41M.
What does cash and cash equivalents, end of period mean?
Cash and cash equivalents, end of period

Ask your AI about Zevra Therapeutics, Inc.'s cash and cash equivalents, end of period.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude